Abstract:ETHNOPHARMACOLOGICAL RELEVANCE:The morphological characteristics of Ganoderma cochlear (Blume & T. Nees) Bres were identical to G. sinsense J.D. Zhao, L.W. Hsu & X.Q. Zhang, however, with the fungus stipe lying in the back of the pileus. Fruiting bodies and spores of G. cochear have been traditionally used for smoothing, sleeping improvement, memory impairment, anti-aging, and prolonging life. Alzheimer's disease (AD) is a chromic progressive neurodegenerative disorder associated with loss of memory and cognition. Hallmarks of AD include aging, amyloid-β plaques, neurofibrillary tangles, neuron loss, neuronal degeneration, network disruption, cognitive dysfunction, inflammation and oxidation stress. In this study, norlanostanoids from G. cochear are identified as potential neurotrophic chemists related to the memory impairment usage to slow down pathogenetic process and restore neural circuits for AD.AIM OF STUDY:Chemical and biological investigations in this study uncovered the potential constituents related to the traditional usage of G. cochlear.MATERIALS AND METHODS:The extract of the mushrooms was purified using various column chromatography techniques and high-performance liquid chromatography (HPLC). The structures of the isolates were elucidated by combination of spectral, and single crystal X-ray diffraction analysis. The neurotrophic activity was evaluated by the differentiation state of PC12 cells, and the dose-dependent and time-dependant expression of growth-associated protein (GAP-43) was analyzed by western blotting.RESULTS:Ganorbifates J-T (1-11), eleven previously undescribed triterpenoids together with five known trinorlanostanoids (12-16) were isolated from the fruiting bodies of G. Cochlear. Among them, ganorbifates N-O (5-6) had a demethylation at C-28 compared to the classic skeleton of 3,4-seco-25,26,27-trinorlanostanoids to form a new group of 3,4-seco-25,26,27,28-tetranorlanostanoids. Based on this, a novel skeleton of ganorbifate M (4) was further established by the arrangement of C-29 from C-4 to C-7. A plausible biosynthetic pathway of compounds 4-6 was proposed. Eight of the sixteen isolates showed neurotrophic activity with the concentration of 10 μM. Furthermore, compound 15 exhibited a dose-dependent neurogenic activity, and also strengthened the expression of the growth-associated protein (GAP-43) in NGF-induced PC-12 cells, whereas 11 showed an inhibitory effect at higher concentration.CONCLUSION:These results demonstrated that 3,4-seco-norlanostanoids had reliable potential in promoting the outgrowth of PC-12 cells and could be used in the prevention and treatment of Alzheimer's disease, which is consist with the beneficial effects of G. Cochlear.

Highly Oxygenated Chemical Constitutes and Rearranged Derivatives with Neurotrophic Activity from Ganoderma Cochlear

Pharmacological Effects of Natural Ganoderma and Its Extracts on Neurological Diseases: A Comprehensive Review

Ganoderma Lucidum Triterpenoids (glts) Reduce Neuronal Apoptosis Via Inhibition of ROCK Signal Pathway in APP/PS1 Transgenic Alzheimer's Disease Mice

Polysaccharides from Ganoderma lucidum Promote Cognitive Function and Neural Progenitor Proliferation in Mouse Model of Alzheimer's Disease

Metabolites from the Mushroom Ganoderma Lingzhi As Stimulators of Neural Stem Cell Proliferation.

Triterpenoids and Meroterpenoids from the Edible Ganoderma Resinaceum and Their Potential Anti-Inflammatory, Antioxidant and Anti-Apoptosis Activities

COX-2 and iNOS inhibitory epimeric meroterpenoids from Ganoderma cochlear and structure revision of cochlearol Q

The Biological Activity of Ganoderma lucidum on Neurodegenerative Diseases: The Interplay between Different Active Compounds and the Pathological Hallmarks

Triterpenoids with neurotrophic activity from Ganoderma lucidum.

Integration of network pharmacology and molecular docking to explore the molecular mechanism of Cordycepin in the treatment of Alzheimer's disease

Triterpenes and Aromatic Meroterpenoids with Antioxidant Activity and Neuroprotective Effects from Ganoderma lucidum

Ganoderic acid a alleviates Aβ25−35-induced HT22 cell apoptosis through the ERK/MAPK pathway: a system pharmacology and in vitro experimental validation

(±)-Gancochlearols J − N, renoprotective meroterpenoids from Ganoderma cochlear

Polyhydroxy Sterols Isolated From Ganoderma sinense Spores and Their Cytotoxic Activities

Terminal Cyclohexane-Type Meroterpenoids from the Fruiting Bodies of Ganoderma cochlear

Ganoderterpene A, a New Triterpenoid from Ganoderma Lucidum, Attenuates LPS-Induced Inflammation and Apoptosis Via Suppressing MAPK and TLR-4/NF-κB Pathways in BV-2 Cells.

Structural characterization of a galactoglucomannan with anti-neuroinflammatory activity from Ganoderma lucidum

Neuropharmacological Effect and Clinical Applications of Ganoderma (Lingzhi).

Therapeutic potential of the medicinal mushroom Ganoderma lucidum against Alzheimer's disease

Total Synthesis of Ganoderma Meroterpenoids Cochlearol B and Its Congeners Driven by Structural Similarity and Biological Homology.

Total Synthesis of GanodermaMeroterpenoids Cochlearol B and Its Congeners Driven by Structural Similarity and Biological Homology